LLY compared with VYNE: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

VYNEVYNE Therapeutics Inc.

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

VYNEVYNE Therapeutics Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

VYNE revenue flow unavailable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only LLY 29

MCKMcKessoncustomer

CAHCardinal Healthcustomer

VEEVVeeva Systemssupplier

UTHRUnited Therapeuticscustomer

25 more · LLY chain ›

Shared 0

No disclosed counterparties: VYNE.

Only VYNE 0

None

Role chip = supplier or customerSource: SEC EDGAR

LLYELI Lilly & Co

1,417.89▲+0.60%· post 1,418.50· delayed

Mkt cap$1.3TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

VYNEVYNE Therapeutics Inc.

17.86▼−2.77%· post 14.95· delayed

After hoursNov 4 '26delayed

Mkt cap—Revenue—Revenue—

Compare

After hoursNov 4 '26delayed

LLYELI Lilly & Co

VYNEVYNE Therapeutics Inc.

1,417.89▲+0.60%post 1,418.50delayed

Price

17.86▼−2.77%post 14.95delayed

$1.3T

Mkt cap

—

Q3 FY26$24.4B

Revenue

—

FY25$65.2B

Revenue

—

LLY1,417.89▲+0.60%vsVYNE17.86▼−2.77%After hoursNov 4 '26delayed

Price

rebased to 0%

LLY, solidVYNE, dashed